Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2023-02-09 4:04 pm Sale | 13G | MEI PHARMA INC PAR $ MEIP | UBS Oncology Impact Fund L.P. | 0 0.000% | -10,137,859 (Position Closed) | View |
| 2021-02-16 08:32 am Purchase | 13G | MEI PHARMA INC PAR $ MEIP | UBS Oncology Impact Fund L.P. | 10,137,859 9.000% | 3,887,859 (+62.21%) | View |
| 2021-01-19 4:33 pm Purchase | 13D | CULLINAN THERAPEUTICS INC CGEM | UBS Oncology Impact Fund L.P. | 8,546,093 19.600% | 8,546,093 (New Position) | View |
| 2020-04-08 1:54 pm Sale | 13G | F-star Therapeutics Inc. FSTX | UBS Oncology Impact Fund L.P. | 603,070 3.500% | -833,839 (-58.03%) | View |
| 2020-02-05 2:13 pm Sale | 13G | VIRACTA THERAPEUTICS INC VIRX | UBS Oncology Impact Fund L.P. | 2,809,912 2.500% | -2,146,588 (-43.31%) | View |
| 2020-02-05 2:11 pm Purchase | 13G | MEI PHARMA INC PAR $ MEIP | UBS Oncology Impact Fund L.P. | 6,250,000 5.900% | 6,250,000 (New Position) | View |